Capability
DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty
How does DNA Script's enzymatic DNA synthesis and the SYNTAX benchtop DNA printer enable rapid on-site production of custom oligonucleotides?
DNA Script SAS is a Paris-based deep-tech biotechnology company specializing in enzymatic DNA. Defence-finance analysis; 14-page sourced DFM PDF report.
This public thread presents the concise analytical answer. The complete evidence, source base and assessment are available below.
Part of our Research, Universities & Deep Tech and Defence & Dual-Use Companies coverage →
Original DFM publication · DFM Analysis report · 2025-12-28
DNA Script SAS is a Paris-based deep-tech biotechnology company specializing in enzymatic DNA synthesis . Founded in 2014, it has developed the SYNTAX® platform, the world’s first benchtop DNA “printer,” enabling rapid on-site production of custom oligonucleotides for research and diagnostics.
Headquartered in Le Kremlin-Bicêtre (Paris metropolitan area) , DNA Script maintains additional operations in the United States (South San Francisco, California ) and a global distribution network (e.g. Middle East distributor in Dubai ). Its official website is dnascript.com (with active social media channels for press and support).
This analysis answers: How does DNA Script's enzymatic DNA synthesis and the SYNTAX benchtop DNA printer enable rapid on-site production of custom oligonucleotides? What is the readiness of DNA Script's platform and its relevance to European biological sovereignty and dual-use biodefence? What is DNA Script's footprint (France HQ, US operations, global distribution network) and its partnerships and market strategy? What capability gaps, IP assets and strategic indicators shape DNA Script's contribution to European biotech autonomy?
Key takeaways
- Middle East distributor in Dubai ).
- Its official website is dnascript.com (with active social media channels for press and support).
Choose how to continue
Go deeper on this question
Keep getting the analysis
DFM publishes new defence-finance analysis every week.
Original DFM analysis
DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty
The publication details above identify the source used for this public thread.
FAQ
What is DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty?
Founded in 2014, it has developed the SYNTAX® platform, the world’s first benchtop DNA “printer,” enabling rapid on-site production of custom oligonucleotides for research and diagnostics.
Why does DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty matter for European defence?
Headquartered in Le Kremlin-Bicêtre (Paris metropolitan area) , DNA Script maintains additional operations in the United States (South San Francisco, California ) and a global distribution network (e.g.
Related DFM Platform threads
Explore this category Strategic Autonomy
Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)
See Professional & Institutional Access — plans, group/institutional seats and contact →
Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.